Abstract:Background Accumulating experimental evidence suggests that the microbiome plays an important role in cancer metastasis; however, microbial features of human colorectal cancer (CRC) metastases remain largely unknown. Here, we performed an integrated metagenomic and metabolomic analysis of primary CRC and its associated liver metastases. Methods CRC patients (N=98) who underwent the resection of primary lesions and developed liver metastases were included. Metagenomic and metabolomic analysis was performed on paired CRC tumors, paracancerous normal colon (adj-CRC), liver metastases (LM), and paracancerous normal liver (adj-LM) to profile alteration in the gut microbiome and metabolites by DESeq2. Results Distinct microbiome profiles are observed in paired CRC tumor, adj-CRC, paired LM and adj-LM tissues. Colonic microbiota was dominated by the phyla Firmicutes and Bacteroidetes, whereas Proteobacteria was most abundant in the liver. LM and adj-LM were further separated into two distinct clusters, with significant enrichments of Bacteroides and Fusobacteria in LM compared to adj-LM (P<0.05). Within the Taxonomy >20% prevalence in CRC, the dysregulated proportion of Firmicutes, Actinobacteria and Fusobacteria was found in LM compared to adj-LM. In terms of metabolomic profiling, amino acids metabolism and energy production were dysregulated in LM. Integrative analyses revealed that many microbial-metabolite connections showed a similar trend among CRC and LM tissues. Notably, the abundance of Ruminococcus, Christensenellaceae, Fretibacterium, Ruminococcaceae, and Intestinimonas was significantly higher in CRC patients with post-operative recurrence compared to the patients with no recurrence. These microbes were also associated with patient poor survival. Besides, we identified 12-hydroxy-12-octadecanoylcarnitine and 3-hydroxy-9Z-octadecenoyl-carnitine as metabolites that were concomitantly enriched in both primary CRC and recurrent LM. These microbial and metabolite biomarkers, respectively, predict patient survival and recurrence of LM in CRC. Conclusions We identified the microbiome and metabolic signatures in primary CRC that are associated with LM, which may play an important role in driving liver metastases.

Gut Microbiota Alteration Influences Colorectal Cancer Metastasis to the Liver by Remodeling the Liver Immune Microenvironment

Alterations of the Gut Microbiome and Fecal Metabolome in Colorectal Cancer: Implication of Intestinal Metabolism for Tumorigenesis

How Gut Microbiota May Influence Colorectal Cancer Metastatic Potential

Disease-associated Gut Microbiome and Critical Metabolomic Alterations in Patients with Colorectal Cancer

Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer

Fusobacterium nucleatum promotes liver metastasis in colorectal cancer by regulating the hepatic immune niche and altering gut microbiota

IDDF2023-ABS-0250 Comprehensive Analyses of Microbiome and Metabolism Reveal Liver Metastasis-Specific Signature in Colorectal Cancer

Integrated analysis of gut microbiota and metabolomic profiling in colorectal cancer metastasis

Colorectal cancer-specific microbiome in peripheral circulation and cancer tissues

Alterations in the gut microbiota and their metabolites in human intestinal epithelial cells of patients with colorectal cancer

Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation

Alterations in the Gut Microbiota and Their Metabolites in Colorectal Cancer: Recent Progress and Future Prospects

Effects of metronidazole on colorectal cancer occurrence and colorectal cancer liver metastases by regulating Fusobacterium nucleatum in mice

Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer

Probiotics and the Role of Dietary Substrates in Maintaining the Gut Health: Use of Live Microbes and Their Products for Anticancer Effects against Colorectal Cancer

Gut Microbiota-Derived Metabolites in Colorectal Cancer: The Bad and the Challenges

Effect of gut microbiota in the colorectal cancer and potential target therapy

The Roles of Gut Microbiota Metabolites in the Occurrence and Development of Colorectal Cancer: Multiple Insights for Potential Clinical Applications

Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer

Unveiling the covert interaction between gut microbiota and neutrophils to drive colorectal cancer metastasis

KRAS mutations promote the intratumoral colonization of enterotoxigenic bacteroides fragilis in colorectal cancer through the regulation of the miRNA3655/SURF6/IRF7/IFNβ axis